Shareholder group in Alaunos Therapeutics (TCRT) proposes $7M control-shifting investment

Rhea-AI Filing Summary

Alaunos Therapeutics’ shareholders led by Adrian Price filed Amendment No. 4 to their Schedule 13D and proposed a major new financing and governance change. The group reports beneficial ownership of 189,061 shares of common stock, representing 8.6% of the company.

In a letter dated February 24, 2026, Price proposed that HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited invest $7,000,000 in equity or equity-linked securities via a private placement, with pricing to be negotiated and closing after board approval, documentation and any required Nasdaq shareholder approval. The letter says this transaction, if completed, is expected to result in a change of control.

The shareholders asked the board to meet within five business days to negotiate terms, pressed for the appointment of Gerald Bruce as a director, and stated they may buy additional shares, pursue a tender offer or launch an investor relations campaign if the board does not engage. Amendment No. 4 also corrects and updates the list of reporting persons, their addresses and related powers of attorney.

Insights

Activist investing and corporate governance analyst

Shareholder group with 8.6% stake proposes a $7M change-of-control financing.

A group of investors reporting 8.6% of Alaunos Therapeutics’ common stock has updated its disclosure and sent a detailed proposal to the board. The proposal contemplates a $7,000,000 private placement in equity or equity-linked securities by three affiliated investors.

The letter states that, if completed, this financing is anticipated to result in a change of control, which could materially reshape governance and strategic direction. Terms, including pricing, would be negotiated in good faith and would require board approval, definitive documents and any shareholder approval required under Nasdaq rules.

The investors also nominated Gerald Bruce to the board and indicated they may pursue additional share purchases, a tender offer or an investor-relations campaign if engagement does not occur within five business days of the February 24, 2026 letter. Actual impact will depend on the board’s response and the outcome of any negotiations or alternative actions.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 4)

Alaunos Therapeutics, Inc.

(Name of Issuer)

Common stock

(Title of Class of Securities)

Samuel E. Whitley
24285 Katy Freeway, Suite 300,
Katy, TX, 77494
2812060434

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

02/24/2026

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Price Adrian

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

189,061.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.6 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Chris Butterworth

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 10,700.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 10,700.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

10,700.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.5 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Richard Jones

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 16,000.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 16,000.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

16,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.7 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Edward Jones

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 11,750.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 11,750.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

11,750.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.5 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Gareth Downing

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 19,552.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 19,552.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

19,552.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.9 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Richard Kotey

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 12,530.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 12,530.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

12,530.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.6 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Chris Cole

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 15,856.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 15,856.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

15,856.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.7 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Arif Chaudrey

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 6,423.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 6,423.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

6,423.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Emma Babb

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 10,366.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 10,366.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

10,366.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.5 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Colin Craig

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,000.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 7,000.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

7,000.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

John Nicholls

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 16,743.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 16,743.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

16,743.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Carl Ware

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 1,721.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 1,721.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

1,721.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Andrew Turner

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 13,035.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 13,035.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

13,035.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.6 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Matthew Robbins

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 10,036.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 10,036.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

10,036.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.5 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Phillip James Stead

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 11,012.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 11,012.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

11,012.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.5 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Stephen Hennessy

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 7,108.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 7,108.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

7,108.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.3 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Greg Arnold

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 10,735.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 10,735.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

10,735.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.5 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Michelle Douglas

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

PF

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 8,494.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 8,494.00
10	Shared Dispositive Power 189,061.00

11

Aggregate amount beneficially owned by each reporting person

8,494.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.4 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

HexagonONE Ltd

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Alimenta Holding Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP Number(s):

1

Name of reporting person

Krakatau Holding Limited

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

WC

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

VIRGIN ISLANDS, BRITISH

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 189,061.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

0.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.0 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common stock
(b)	Name of Issuer: Alaunos Therapeutics, Inc.
(c)	Address of Issuer's Principal Executive Offices: 501 E LAS OLAS BLVD, SUITE 300, FORT LAUDERDALE, TEXAS , 33301.
Item 1 Comment: This Amendment No. 4 is being filed to correct the names of the Reporting Persons reported in Amendment No. 3 (the "New Reporting Persons"), add the addresses of the New Reporting Persons, attach powers of attorney for the New Reporting Persons, and attach a Joint Filing Agreement for the Reporting Persons.
Item 2.	Identity and Background
(a)	The below persons are collectively referred to herein as the Reporting Persons. Each of the Reporting Persons files this Schedule 13D jointly. The Reporting Persons are filing this Schedule 13D jointly, as they may be considered a Group under Section 13(d)(3) of the Act. However, neither the fact of this filing nor anything contained herein shall be deemed to be an admission by the Reporting Persons that such a group exists. Chris Butterworth Richard Jones Edward Jones Gareth Downing Richard Kotey Chris Cole Arif Chaudrey Emma Babb Colin Craig John Nicholls Carl Ware Andrew Turner Matthew Robbins Phillip James Stead Stephen Hennessy Greg Arnold Michelle Douglas HexagonONE Ltd Krakatau Holding Limited Alimenta Holding Limited
(b)	Chris Butterworth: 12A Grahamshill Street, Airdrie, ML6 7EN, United Kingdom Richard Jones: 28 Jedburgh Street, Blantyre, Glasgow, South Lanarkshire, G72 0SU, United Kingdom Edward Jones: 21 Langdale Avenue, Formby, Liverpool, L37 2LB, United Kingdom Gareth Downing: 14 Osier Way, Banstead, SM7 1LL, United Kingdom Richard Kotey: 13 Mendez Way, London, SW15 5GA, United Kingdom Chris Cole: 18 Herons Way, Hayling Islang, Hants, PO11 9FL, United Kingdom Arif Chaudrey: 25 Bays Crescent, Spencers Wood, Reading, RG7 1DF, United Kingdom Emma Babb: 71 Stanborrough Avenue, Borhamwood, Harts, WD6 5LX, United Kingdom Colin Craig: 43 Inverary Drive, Belfast, BT4 1RD, United Kingdom John Nicholls: 41 Lea Castle Drice, Lea Castle, Kiddermister, Worcs, DY10 3FB, United Kingdom Carl Ware: 20 Roveley Court, Stony Stratford, Milton Keynes, MK11 1NU, United Kingdom Andrew Turner: 26 Sun Vale Avenue, Todmorden, West Yorkshire, OL14 6TP, United Kingdom Matthew Robbins: 42 Tattersall Road, Yate, Bristol, BS37 7GW, United Kingdom Phillip James Stead: 113 Dartmouth Avenue, Wallsal, West Midlands, WS3 1SP, United Kingdom Stephen Hennessy: 57 Regent House, Station Road, Strood, Kent, ME2 4WQ, United Kingdom Greg Arnold: 1 Hickling Close, Long Eaton, Nottingham, NG10 3TE, United Kingdom Michelle Douglas: 13 Mendez Way, London, SW15 5GA, United Kingdom HexagonONE Ltd: Oleander Building, Suites OL-7 & OL-8, 13A J.R. O'Neal Drive, Port Purcell, Tortola, British Virgin Islands Krakatau Holding Limited: Keyway Chambers, 3rd Floor, Quastisky Building, Road Town, Tortola, British Virgin Islands Alimenta Holding Limited: Keyway Chambers, 3rd Floor, Quastisky Building, Road Town, Tortola, British Virgin Islands
(c)	Chris Butterworth: self-employed electrician;12A Grahamshill Street, Airdrie, ML6 7EN, United Kingdom Richard Jones: manager at Balfour Beatty; Huntly Road, Glasgow, G52 4DZ, United Kingdom Edward Jones: self-employed software developer; 21 Langdale Avenue, Formby, Liverpool, L37 2LB, United Kingdom Gareth Downing: ops manager at M Group; Gunnells Eood Rd, Stevenage, United Kingdom Richard Kotey: tutor at United Colleges Group; 26 Paddington Green, W2 1NB, United Kingdom Chris Cole: self-employed carpenter; 18 Herons Way, Hayling Islang, Hants, PO11 9FL, United Kingdom Arif Chaudrey: petroleum engineer at KBR Consulting; KT22 7NL, Letterhead, United Kingdom Emma Babb: housewife; 71 Stanborrough Avenue, Borhamwood, Harts, WD6 5LX, United Kingdom Colin Craig: support worker/subcontractor at various companies; 43 Inverary Drive, Belfast, BT4 1RD, United Kingdom John Nicholls: field service engineer at Clearmark Solutions; Olympic House, Nottingham, NG15 0DP, United Kingdom Carl Ware: self-employed IT consultant; 20 Roveley Court, Stony Stratford, Milton Keynes, MK11 1NU, United Kingdom Andrew Turner: ops manager at Urbasers; 3 Sidings Court, Doncaster DN4 5NU, United Kingdom Matthew Robbins: student at Bristol University; Beacon House Bristol, BS8 1QU, United Kingdom Phillip James Stead: events manager at Walsal FC; Beacon House Bristol, BS8 1QU, United Kingdom Stephen Hennessy: engineer at Go Fix; Beechcroft Farm ind estate, TN15 7HX, United Kingdom Greg Arnold: project supervisor at CITY; Caldonia House Glasgow, United Kingdom Michelle Douglas: manager at NHS; PO Box 130, Morden, SM4 9EF, United Kingdom HexagonONE Ltd: unknown Krakatau Holding Limited: unknown Alimenta Holding Limited: unknown
(d)	Chris Butterworth: No Richard Jones: No Edward Jones: No Gareth Downing: No Richard Kotey: No Chris Cole: No Arif Chaudrey: No Emma Babb: No Colin Craig: No John Nicholls: No Carl Ware: No Andrew Turner: No Matthew Robbins: No Phillip James Stead: No Stephen Hennessy: No Greg Arnold: No Michelle Douglas: No HexagonONE Ltd: No Krakatau Holding Limited: No Alimenta Holding Limited: No
(e)	Chris Butterworth: No Richard Jones: No Edward Jones: No Gareth Downing: No Richard Kotey: No Chris Cole: No Arif Chaudrey: No Emma Babb: No Colin Craig: No John Nicholls: No Carl Ware: No Andrew Turner: No Matthew Robbins: No Phillip James Stead: No Stephen Hennessy: No Greg Arnold: No Michelle Douglas: No HexagonONE Ltd: No Krakatau Holding Limited: No Alimenta Holding Limited: No
(f)	Chris Butterworth: United Kingdom Richard Jones: United Kingdom Edward Jones: United Kingdom Gareth Downing: United Kingdom Richard Kotey: United Kingdom Chris Cole: United Kingdom Arif Chaudrey: United Kingdom Emma Babb: United Kingdom Colin Craig: United Kingdom John Nicholls: United Kingdom Carl Ware: United Kingdom Andrew Turner: United Kingdom Matthew Robbins: United Kingdom Phillip James Stead: United Kingdom Stephen Hennessy: United Kingdom Greg Arnold: United Kingdom Michelle Douglas: United Kingdom HexagonONE Ltd: British Virgin Islands Krakatau Holding Limited: British Virgin Islands Alimenta Holding Limited: British Virgin Islands
Item 3.	Source and Amount of Funds or Other Consideration
	Chris Butterworth: personal funds Richard Jones: personal funds Edward Jones: personal funds Gareth Downing: personal funds Richard Kotey: personal funds Chris Cole: personal funds Arif Chaudrey: personal funds Emma Babb: personal funds Colin Craig: personal funds John Nicholls: personal funds Carl Ware: personal funds Andrew Turner: personal funds Matthew Robbins: personal funds Phillip James Stead: personal funds Stephen Hennessy: personal funds Greg Arnold: personal funds Michelle Douglas: personal funds HexagonONE Ltd: working capital Krakatau Holding Limited: working capital Alimenta Holding Limited: working capital
Item 4.	Purpose of Transaction
	On February 24, 2026, counsel for Adrian Price sent a letter on behalf of the Reporting Persons to counsel of Alaunos Therapeutics, Inc. (the "Company"), and requested that the Company's counsel provide the letter to the Company's Board of Directors ("Board"). In this letter, Mr. Price proposed a private placement whereby HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited (the "Investors") would purchase $7,000,000 of securities of the Company subject to mutually agreeable definitive documentation and customary closing conditions. The securities purchased by the Investors would be equity or equity-linked securities, with the purchase price to be negotiated in good faith, taking into account market conditions, the Company's liquidity needs, and long-term shareholder alignment. The Investors proposed that the private placement close as soon as practicable following Board approval and completion of documentation and shareholder approval (if required by Nasdaq rules). The letter requested the Board meet with Mr. Price within five business days to begin term sheet negotiation and due diligence. The letter also reiterated the Reporting Persons' nomination of Gerald Bruce to the Board and requested that the Board appoint Mr. Bruce as a director. The letter stated that if the Board did not engage meaningfully with Mr. Price within this five business day period, then the Reporting Persons may seek to purchase additional shares of the Company in the market or undertake a tender offer to shareholders. The letter also mentioned that the Reporting Persons could undertake an investor relations campaign if the Board did not engage meaningfully with Mr. Price. In the letter, Mr. Price reserved all rights belonging to the Reporting Persons as shareholders of the Company. If consummated, it its anticipated that the proposed private placement would result in a change of control of the Company. The letter sent by Mr. Price is attached hereto as Exhibit 21. This letter was sent as part of the Reporting Persons' efforts to help create shareholder value, and the Reporting Persons intend to continue these efforts. The Reporting Persons may purchase and sell common stock of the Company in their sole discretion and at such times as they deem convenient, subject to applicable law. Other than as set forth above, the Reporting Persons do not intend to take any other actions described in subsections (a) through (j) of Item 4 of Schedule 13D at this time; however, they reserve the right to do so.
Item 5.	Interest in Securities of the Issuer
(a)	The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto), and in Items 2 and 3 of this amendment, are incorporated by reference into this Item 5. Adrian Price disclaims beneficial ownership of the securities discussed herein.
(b)	The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto), and in Items 2 and 3 of this amendment, are incorporated by reference into this Item 5. Adrian Price disclaims beneficial ownership of the securities discussed herein.
(c)	The Reporting Persons have not conducted any transactions in Alaunos securities in the past 60 days.
(d)	N/A
(e)	N/A
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	The Reporting Persons have entered into a Joint Filing Agreement, which is set forth hereto as Exhibit 1 and incorporated by reference, and Exhibit 22. The Reporting Persons have granted Adrian Price a power of attorney to sign and file this Schedule 13D (and any amendments) and the Joint Filing Agreement with the Securities and Exchange Commission. These powers of attorney are set forth as Exhibits 23-25. Other than as described herein, there are no contracts, arrangements, understandings or relationships among the Reporting Persons, or between the Reporting Persons and any other person, with respect to the securities of Alaunos.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 Joint Filing Agreement, incorporated by reference Exhibit 2 Power of Attorney: Chris Butterworth, incorporated by reference Exhibit 3 Power of Attorney: Richard Jones, incorporated by reference Exhibit 4 Power of Attorney: Edward Jones, incorporated by reference Exhibit 5 Power of Attorney: Gareth Downing, incorporated by reference Exhibit 7 Power of Attorney: Richard Kotey, incorporated by reference Exhibit 8 Power of Attorney: Chris Cole, incorporated by reference Exhibit 9 Power of Attorney: Arif Chaudrey, incorporated by reference Exhibit 10 Power of Attorney: Emma Babb, incorporated by reference Exhibit 11 Power of Attorney: Colin Craig, incorporated by reference Exhibit 12 Power of Attorney: John Nicholls, incorporated by reference Exhibit 13 Power of Attorney: Carl Ware, incorporated by reference Exhibit 14 Power of Attorney: Andrew Turner, incorporated by reference Exhibit 15 Power of Attorney: Matthew Robbins, incorporated by reference Exhibit 16 Power of Attorney: Phillip James Stead, incorporated by reference Exhibit 17 Power of Attorney: Stephen Hennessy, incorporated by reference Exhibit 18 Power of Attorney: Greg Arnold, incorporated by reference Exhibit 19 Power of Attorney: Michelle Douglas, incorporated by reference Exhibit 20 Letter to Alaunos Board of Directors, incorporated by reference Exhibit 21 Proposal to the Board of Directors of Alaunos Therapeutics (TCRT), incorporated by reference Exhibit 22 Joint Filing Agreement for HexagonONE Ltd, Krakatau Holding Limited, and Alimenta Holding Limited Exhibit 23 Power of Attorney: HexagonONE Ltd Exhibit 24 Power of Attorney: Krakatau Holding Limited Exhibit 25 Power of Attorney: Alimenta Holding Limited

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Price Adrian

Signature:	Adrian Price
Name/Title:	Adrian Price, self
Date:	02/24/2026

Chris Butterworth

Signature:	Chris Butterworth
Name/Title:	Chris Butterworth by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Richard Jones

Signature:	Richard Jones
Name/Title:	Richard Jones by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Edward Jones

Signature:	Edward Jones
Name/Title:	Edward Jones by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Gareth Downing

Signature:	Gareth Downing
Name/Title:	Gareth Downing by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Richard Kotey

Signature:	Richard Kotey
Name/Title:	Richard Kotey by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Chris Cole

Signature:	Chris Cole
Name/Title:	Chris Cole by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Arif Chaudrey

Signature:	Arif Chaudrey
Name/Title:	Arif Chaudrey by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Emma Babb

Signature:	Emma Babb
Name/Title:	Emma Babb by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Colin Craig

Signature:	Colin Craig
Name/Title:	Colin Craig by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

John Nicholls

Signature:	John Nicholls
Name/Title:	John Nicholls by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Carl Ware

Signature:	Carl Ware
Name/Title:	Carl Ware by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Andrew Turner

Signature:	Andrew Turner
Name/Title:	Andrew Turner by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Matthew Robbins

Signature:	Matthew Robbins
Name/Title:	Matthew Robbins by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Phillip James Stead

Signature:	Phillip James Stead
Name/Title:	Phillip James Stead by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Stephen Hennessy

Signature:	Stephen Hennessy
Name/Title:	Stephen Hennessy by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Greg Arnold

Signature:	Greg Arnold
Name/Title:	Greg Arnold by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Michelle Douglas

Signature:	Michelle Douglas
Name/Title:	Michelle Douglas by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

HexagonONE Ltd

Signature:	HexagonONE Ltd
Name/Title:	HexagonONE Ltd by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Alimenta Holding Limited

Signature:	Alimenta Holding Limited
Name/Title:	Alimenta Holding Limited by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

Krakatau Holding Limited

Signature:	Krakatau Holding Limited
Name/Title:	Krakatau Holding Limited by Adrian Price as Attorney-in-Fact
Date:	02/24/2026

FAQ

What ownership stake in Alaunos Therapeutics (TCRT) do the reporting persons disclose?

The reporting persons disclose beneficial ownership of 189,061 shares of Alaunos Therapeutics common stock, representing 8.6% of the class. Individual participants report smaller direct holdings, while this 8.6% figure reflects the aggregate amount shown for one reporting person’s cover page.

What financing proposal did Adrian Price present to the Alaunos Therapeutics (TCRT) board?

Adrian Price proposed a $7,000,000 private placement to Alaunos Therapeutics’ board. Three investors—HexagonONE Ltd, Alimenta Holding Limited and Krakatau Holding Limited—would buy equity or equity-linked securities, with pricing negotiated in good faith and closing after board approval, documentation and any required Nasdaq shareholder approval.

Could the proposed $7,000,000 investment result in a change of control at Alaunos Therapeutics (TCRT)?

Yes. The filing states that, if consummated, the proposed $7,000,000 private placement is anticipated to result in a change of control of Alaunos Therapeutics. This expectation is tied to the contemplated equity or equity-linked securities purchase by the three identified investor entities.

What conditions apply to the proposed private placement in Alaunos Therapeutics (TCRT)?

The proposed private placement is subject to board approval, mutually agreeable definitive documentation and shareholder approval if required by Nasdaq rules. Pricing would be negotiated in good faith, taking into account market conditions, the company’s liquidity needs and long-term shareholder alignment before closing.

What actions might the reporting persons take if the Alaunos Therapeutics (TCRT) board does not engage?

The letter states that, absent meaningful engagement within five business days, the reporting persons may buy additional shares in the market, pursue a tender offer to shareholders, or undertake an investor relations campaign, while reserving all rights as shareholders.

What is the main purpose of Amendment No. 4 to the Alaunos Therapeutics (TCRT) Schedule 13D?

Amendment No. 4 primarily corrects and updates the reporting persons’ information, including their names and addresses, adds powers of attorney, and attaches a new joint filing agreement. It also describes the detailed $7,000,000 private placement and governance proposal sent to the company’s board.

What board changes are the reporting persons seeking at Alaunos Therapeutics (TCRT)?

The reporting persons reiterate their nomination of Gerald Bruce to Alaunos Therapeutics’ board and request that the board appoint him as a director. This governance request is included alongside the proposed $7,000,000 private placement in the February 24, 2026 letter.